Literature DB >> 3164242

Chromosome imbalance in endometrial adenocarcinoma.

J Couturier1, P Vielh, R J Salmon, M Lombard, B Dutrillaux.   

Abstract

The results of karyotypic analysis by R-banding after short-term culture of eight new cases of endometrial adenocarcinomas are presented and compared to previously published data. Among a total of 25 cases reported that had a diploid or near-diploid chromosome number, 72% contained a trisomy or tetrasomy 1q, often as the only abnormality. An excess of the long arm of chromosome 1 is, therefore, shown to be the predominant feature of endometrial adenocarcinoma. Trisomies 10, 2, 7, and 12 were, in decreasing order, the most frequently associated abnormalities, but trisomy 10, found in 40% of the cases, can also exist as the only imbalance. Because breakpoints in chromosome 1 are generally centromeric, a position effect with oncogene activation seems unlikely. It is suggested that the observed chromosome imbalances are secondary and are the result of the adaptation of the cancer cell to disturbed metabolic pathways.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3164242     DOI: 10.1016/0165-4608(88)90051-9

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  3 in total

1.  Breast cancer genetic evolution: I. Data from cytogenetics and DNA content.

Authors:  B Dutrillaux; M Gerbault-Seureau; Y Remvikos; B Zafrani; M Prieur
Journal:  Breast Cancer Res Treat       Date:  1991-11       Impact factor: 4.872

2.  The effect of first chromosome long arm duplication on survival of endometrial carcinoma.

Authors:  Erman Sever; Emek Doğer; Yiğit Çakıroğlu; Deniz Sünnetçi; Naci Çine; Hakan Savlı; İzzet Yücesoy
Journal:  Turk J Obstet Gynecol       Date:  2014-12-15

3.  Purine and pyrimidine metabolism in human gliomas: relation to chromosomal aberrations.

Authors:  V Bardot; A M Dutrillaux; J Y Delattre; F Vega; M Poisson; B Dutrillaux; C Luccioni
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.